Australia News
Filter News
Found 7,114 articles
-
Genetic Technologies Announces $6.56 Million Registered Direct Offering
1/21/2021
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,250,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.25 per ADS
-
Immutep Quarterly Activities Report
1/21/2021
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.
-
Ulcerative Colitis Phase II Study of GSK2831781 DiscontinuedImmutep’s Collaboration and Exclusive License with GSK Remains in Place
1/21/2021
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis.
-
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
1/21/2021
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.
-
SOPHiA GENETICS Appoints Influential Regulatory Figure Kathy L. Hibbs to Board of Directors
1/19/2021
SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Kathy L. Hibbs was nominated to the company's Board of Directors and its Audit Committee
-
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
1/18/2021
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers.
-
Orthocell Receives US Market Clearance
1/15/2021
Australian-based regenerative medicine company, Orthocell Ltd, has achieved US 510k clearance to market and supply its collagen medical device Striate+TM in the US dental bone and tissue regeneration market.
-
Agilex Biolabs Announces Start of GALEXI™ Client Portal Roll-out at Biotech Showcase 2021
1/13/2021
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
-
AVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results
1/12/2021
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2020.
-
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
1/11/2021
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today analyzes pancreatic proenzymes versus T-Cell therapy when targeting solid tumors such as pancreatic, ovarian and colorectal cancers. The analysis is prepared by the Company’s Chief Executive Officer, Mr. James Nathaniel
-
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
1/11/2021
Immuron Limited, an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright & Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week.
-
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study
1/7/2021
Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part C of its TACTI-002 Phase II study.
-
Dr David Stamler Appointed CEO
1/7/2021
The Board of Alterity Therapeutics is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
-
Liquid Instruments Enhances Executive Team and Board of Directors Ahead of Expansion to New Markets
1/6/2021
Seasoned experts across physics and electronics industries bring experience from Texas Instruments, Los Alamos National Laboratory and Xilinx to guide further growth in R&D, manufacturing and education markets
-
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market
12/30/2020
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The
-
Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
12/30/2020
- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize - The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing
-
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
12/29/2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office.
-
Novotech Health Holdings Appoints Zidong Zhang as CFO
12/29/2020
Novotech Health Holdings, the largest biotech specialist contract research organization in Asia, announced the appointment of Zidong Zhang as Chief Financial Officer effective 4 January 2021.